Evaluating the Utility of Proteomics for the Identification of Circulating Pharmacodynamic Biomarkers of <scp>IFNβ</scp> ‐1a Biologics-Reference-Cited by-同舟云学术

Evaluating the Utility of Proteomics for the Identification of Circulating Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics

Published:2022-11-19 Issue:1 Volume:113 Page:98-107
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Hyland Paula L.¹,Chekka Lakshmi Manasa S.¹,Samarth Deepti P.¹,Rosenzweig Barry A.¹,Decker Erica¹^ORCID,Mohamed Esraa G.¹,Guo Yan¹,Matta Murali K.¹^ORCID,Sun Qin²,Wheeler William³,Sanabria Carlos⁴,Weaver James L.¹^ORCID,Schrieber Sarah J.⁵,Florian Jeffry¹,Wang Yow‐Ming²^ORCID,Strauss David G.¹^ORCID

Affiliation:

1. Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences Center for Drug Evaluation and Research, US Food and Drug Administration Silver Spring Maryland USA

2. Therapeutic Biologics Protein Team, Office of Clinical Pharmacology, Office of Translational Sciences Center for Drug Evaluation and Research, US Food and Drug Administration Silver Spring Maryland USA

3. Information Management Services, Inc. Rockville Maryland USA

4. Spaulding Clinical Research West Bend Wisconsin USA

5. Office of Therapeutic Biologics and Biosimilars, Office of New Drugs Center for Drug Evaluation and Research, US Food and Drug Administration Silver Spring Maryland USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2778

Reference41 articles.

1. US Food and Drug Administration.FDA Guidance: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product(2015). Accessed 1 May 2022.

2. Advancing Biosimilar Development Using Pharmacodynamic Biomarkers in Clinical Pharmacology Studies

3. Use of pharmacodynamic/response biomarkers for therapeutic biologics regulatory submissions

4. US Food and Drug Administration.FDA Guidance: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product(2016). Accessed 1 May 2022.

5. “Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity;Pharmaceuticals;2023-11-02

2. A Proposed Global Medicines Agency (GMA) to Make Biological Drugs Accessible: Starting with the League of Arab States;Healthcare;2023-07-20

3. New science, drug regulation, and emergent public health issues: The work of FDA’s division of applied regulatory science;Frontiers in Medicine;2023-01-19

4. Advancing Innovations in Biosimilars;Clinical Pharmacology & Therapeutics;2022-12-22

5. Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and Approval;Clinical Pharmacology & Therapeutics;2022-11-02